AXIATIDE - Teriparatide is a sterile solution for injection containing teriparatide (recombinant human parathyroid hormone 1-34). It is produced by using a strain of E. coli employing recombinant DNA technology. Its sequence is identical to that of 34 N-terminal amino acids (the biologically active region) of the endogenous 84-amino acid human parathyroid hormone. It is a water-soluble protein with a molecular weight of 4117.8 Daltons.

Benefit of Teriparatide Treatment of postmenopausal osteoporosis with 20 mcg teriparatide daily doses decreases the risk of vertebral fractures and non-vertebral fractures significantly.

For the treatment of postmenopausal women with osteoporosis at high risk for fracture, patients who have failed or are intolerant to other available osteoporosis therapy. To increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy. For the treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy who are at high risk for fracture.